Navigation Links
Lancet study supports new, highly effective treatment for blood disorder
Date:3/20/2009

NEW YORK (March 20, 2009) -- Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health. There are estimated to be between 50,000 and 100,000 individuals in the U.S. diagnosed with chronic immune thrombocytopenic purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, rarely, life-threatening brain hemorrhages.

Promacta (eltrombopag) was granted accelerated approval by the U.S. Food and Drug Administration in November 2008 for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promising results of an international, multicenter Phase III clinical trial, led by NewYork-Presbyterian/Weill Cornell researchers, were the basis of this approval and are published in a recent issue of the Lancet.

"Findings from the new study are very encouraging, and I believe this treatment is an effective option for all patients suffering from chronic ITP," says Dr. James Bussel, principal investigator of the study; attending pediatrician and director of the Program for Platelet Disorders at NewYork-Presbyterian Hospital/Weill Cornell Medical Center; and professor of pediatrics, and professor of pediatrics in medicine at Weill Cornell Medical College.

The study follows a previous Phase II study published late 2007 in the New England Journal of Medicine. This trial showed that eltrombopag was effective in raising platelet counts and lowering bleeding in adult subjects with chronic ITP. The Phase II study's results also determined the most promising dose of 50mg, which was given to all of the experimental subjects in the Phase III study.

The Phase III study tested 114 subjects, who were all 18 years and older, with at least six mont
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
3. Scots and Irish at greater risk of drink-related death, study shows
4. Pilot study shows effectiveness of new, low-cost method for monitoring hand hygiene compliance
5. DOE awards UGA $3.1 million to support complex carbohydrate study nationwide
6. AJCN study shows moderate alcohol consumption related to stronger bones
7. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
8. Study suggests salt might be natures antidepressant
9. Study of protein structures reveals key events in evolutionary history
10. American carnivores evolved to avoid each other, new study suggests
11. Sea Grant awards $820,000 for research under EPAs Long Island Sound study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Ebola is a rare, but deadly disease that exists ... One of the most lethal strains is the Sudan ... Africa, SUDV has caused widespread illness, even as recently ... journal ACS Chemical Biology , researchers now report ... infected with SUDV. , John Dye, Sachdev Sidhu, Jonathan ...
(Date:8/27/2014)... Outstanding basic research, a growing focus on ... patient care have earned the Herbert Irving Comprehensive ... (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year ... Institute (NCI). The grant renews the center,s status ... Centers in New York City and one of ...
(Date:8/27/2014)... shown that excessive iron is closely associated ... studies from Chunyan Guo and co-workers from ... that baicalin prevented iron accumulation after substantia ... expression, and increased ferroportin 1 expression in ... rats. However, the relationship between iron concentration ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... team led by British Antarctic Surveys (BAS) Dr Andy Smith ... ice sheet. The lake the size of Lake Windermere ... climate change and future sea-level rise. Glaciologist Dr Smith ... are camped out at one of the most remote places ...
... implications. Should children be tested for gene mutations ... cancer later in life" New research suggests ... even when any steps to reduce that risk will ... current policies., In the study published today online in ...
... PHILADELPHIA - University of Pennsylvania engineers and physicians have ... a human hair that measures electric current and delivers ... tool to probe cells with minimal intrusion and inject ... are found in almost every cell laboratory in the ...
Cached Biology News:Exploration of lake hidden beneath Antarctica's ice sheet begins 2Should children be permitted to get genetic testing for BRCA 1/2 mutations? 2Penn engineers create carbon nanopipettes that are smaller than cells and measure electric current 2
(Date:8/26/2014)... 26, 2014 An analysis by Replikins, Ltd. ... Dengue virus strains in Pubmed, has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
(Date:8/26/2014)... Aug. 26, 2014   Lycera Corp ., ... oral medicines to treat autoimmune disease and cancer ... announced the appointment of Harinder Singh , ... board.  Dr. Singh will lead the board,s efforts ... multiple ongoing research programs and pipeline of therapies ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 The global ... 8,020.1 million by 2020, according to a new study ... medicine and theranostics, and the subsequent introduction of advanced ... driving market growth over the next six years. Moreover, ... diseases such as cancer, coupled with disease triggering lifestyle ...
(Date:8/26/2014)... Genedata, a leading provider of advanced ... research, today announced the Genedata Screener® Global ... Asia, Europe, and North America during September 2014. ... research organizations will gather for annual User Group ... upcoming challenges in all areas of screening. This ...
Breaking Biology Technology:Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... Pharma S.A., a,global specialty pharmaceutical company focused ... company, Galderma Laboratories, Inc., has,completed its acquisition ... result of the transaction, CollaGenex has become ... "We are pleased to complete the acquisition ...
... Signalife, Inc.,(Amex: SGN ) has confirmed that ... and Chief Executive Officer, Dr. Lowell T. Harmison, has,scheduled ... EDT., Dr. Harmison stated: "Now that Signalife has ... manufacturing and shipping,product, I am pleased to provide direction ...
... April 11 Dilon Technologies, Inc., a,manufacturer and ... nine additional Dilon 6800 orders have been secured ... The Dilon 6800, a high-resolution, small field-of-view ... a molecular,breast imaging technique used for the early ...
Cached Biology Technology:Galderma Completes Acquisition of CollaGenex 2Galderma Completes Acquisition of CollaGenex 3Galderma Completes Acquisition of CollaGenex 4Signalife Announces Webcast 2Signalife Announces Webcast 3
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
...
...
Biology Products: